Paxlovid, Molnupiravir Access Threatened By ‘Dismal' Pharmacy Dispensing Fees, CMS Told
Executive Summary
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.
You may also be interested in...
Test To Treat Tug-of-War: Pharmacy, Physician Groups Each Have Concerns With Biden COVID Plan
Community pharmacists say widespread implementation of Biden’s rapid pill dispensing initiative necessitates allowing pharmacists to prescribe Paxlovid and molnupiravir. But AMA worries that even clinic-based prescribing puts patients at risk because it bypasses primary care doctors.
Biden’s ‘Test To Treat’ Plan Will Include Merck And Pfizer COVID Pills, But Only One Gets Public Thanks
Hundreds of pharmacy-based clinics and community health centers will offer free COVID testing and treatment. Government has secured 20 million doses of Pfizer’s Paxlovid, deemed to be a ‘game changer,’ though Merck’s molnupiravir is expected to be important in long-term care facilities.
Coronavirus Update: Paxlovid Moves Towards EU Approval, Moderna Targets Omicron
Pfizer gets European Commission approval for Paxlovid after a positive CHMP opinion, while Moderna started a Phase II study of its Omicron-specific vaccine candidate. Meanwhile, China's Junshi enters into a new oral antiviral collaboration while Daiichi Sankyo investigates its mRNA vaccine contender as a booster shot.